Spectrum Pharmaceuticals, Inc. (SPPI) News
Filter SPPI News Items
SPPI News Results
|Loading, please wait...|
SPPI News Highlights
- SPPI's 30 day story count now stands at 4.
- Over the past 15 days, the trend for SPPI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ACT, LAW and SRTS are the most mentioned tickers in articles about SPPI.
Latest SPPI News From Around the Web
Below are the latest news stories about Spectrum Pharmaceuticals Inc that investors may wish to consider to help them evaluate SPPI as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Spectrum Pharmaceuticals (SPPI), Sensus Healthcare (SRTS) and Verona Pharma (VRNA)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spectrum Pharmaceuticals (SPPI – Research Report), Sensus Healthcare (SRTS – Research Report) and Verona Pharma (VRNA – Research Report) with bullish sentiments. Spectrum Pharmaceuticals (SPPI) In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals, with a price target of $10.00. The company's shares closed last Wednesday at $1.27. According to TipRanks.com, White is a 4-star analyst with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.
HENDERSON, Nev., January 05, 2022--Spectrum Pharmaceuticals Announces Strategic Restructuring
HENDERSON, Nev., January 04, 2022--Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
SHAREHOLDER ALERT: Robbins LLP Investigates Spectrum Pharmaceuticals, Inc. (SPPI) for Misleading Shareholders
SAN DIEGO, CA / ACCESSWIRE / December 22, 2021 / Shareholder rights law firm Robbins LLP is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to determine whether certain Spectrum officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders.
Did You Acquire (SPPI) Before December 27, 2018? Should Spectrum Pharmaceuticals Management be Held Accountable for Investors Losses? Contact Johnson Fistel
SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) against certain of its officers and directors. Recently, a class action complaint was filed against Spectrum. According to the Complaint, the Company made false and misleading statements to the market. Spectrum's manufacturing facility for ROLONTIS failed to maintain appropriate controls and procedures. These d
Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report) and Spectrum Pharmaceuticals (SPPI – Research Report) with bullish sentiments. Anavex Life Sciences (AVXL) In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Anavex Life Sciences, with a price target of $50.00. The company's shares closed last Tuesday at $18.02. According to TipRanks.
In the last trading session, 3.54 million Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) shares changed hands as the companys beta touched 1.90. With the companys per share price at $1.37 changed hands at -$0.21 or -13.29% during last session, the market valuation stood at $259.09M. SPPIs last price was a discount, traded about -282.48% off its 52-week SPPI Stock: More Upside For Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI)? Read More »
The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
HENDERSON, Nev., December 06, 2021--Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib